On May 14, 2015 Roche reported interim results from a global, randomised Phase II study (POPLAR) in people with previously treated NSCLC (Press release, Hoffmann-La Roche , MAY 13, 2015, View Source [SID:1234504269]). The study showed the investigational cancer immunotherapy MPDL3280A (anti-PDL1) doubled the likelihood of survival (overall survival [OS]; HR=0.47) in people whose cancer expressed the highest levels of PD-L1 (programmed death ligand-1) compared with docetaxel chemotherapy. An improvement in survival was also observed in people who had medium and high (HR=0.56) or any level of PD-L1 expression (HR=0.63), as characterised by a test being developed by Roche. MPDL3280A was generally well tolerated and adverse events were consistent with what has been previously reported for MPDL3280A in NSCLC. Updated results will be presented in an oral session at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper). Schedule your 30 min Free 1stOncology Demo! "In our study of MPDL3280A in previously treated lung cancer, the amount of PD-L1 expressed by a person’s cancer correlated with improvement in survival," said Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development. "The goal of PD-L1 as a biomarker is to identify people most likely to experience improved overall survival with MPDL3280A alone and which people may be appropriate candidates for a combination of medicines." Know more, wherever you are: In February 2015, MPDL3280A received Breakthrough Therapy Designation from the FDA for the treatment of people whose NSCLC expresses PD-L1 and who progressed during or after standard treatments (e.g., platinum-based chemotherapy and appropriate targeted therapy for EGFR mutation-positive or ALK-positive disease). Roche is discussing the interim data from POPLAR with the FDA as part of Breakthrough Therapy Designation in lung cancer. Roche currently has three Phase II and six Phase III studies of MPDL3280A ongoing in various kinds of lung cancer.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Latest on Lung Cancer, book your free 1stOncology demo here.
About the POPLAR study
Interim results of the POPLAR study will be presented by Alexander I. Spira, M.D., Ph.D., F.A.C.P, Virginia Cancer Specialists Research Institute; U.S. Oncology Research (Abstract #8010) on Sunday, May 31, 4:42–5:54 P.M. CDT.
Efficacy, safety and predictive biomarker results from a randomised phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). 1
The Phase II study enrolled 287 patients with previously treated, advanced NSCLC. The primary endpoint was OS; secondary endpoints included progression-free survival (PFS), overall response rate (ORR) and safety. Patients were stratified by PD-L1 expression on tumour-infiltrating immune cells (IC), histology and prior lines of therapy. PD-L1 expression was assessed on both tumour cells (TC) and IC; and patients were scored as TC 0, 1, 2, or 3 and IC 0, 1, 2, or 3 with an immunohistochemistry (IHC) test.
CI: confidence interval; Doc: docetaxel; HR: hazard ratio; IC: immune cell; ITT: intention to treat; MPDL: MPDL3280A; NR: not reached; OS: overall survival; TC, tumour cell. *Stratified HR for ITT and unstratified HR for subgroups.
HR: hazard ratio; ITT: intention to treat; NR, not reached. *Stratified HR for ITT and unstratified HR for subgroups.
Fewer people receiving MPDL3280A experienced Grade 3 to 5 adverse events compared to docetaxel (44 percent vs. 56 percent). More respiratory events were reported for MPDL3280A. The median length of treatment with MPDL3280A was 3.7 months compared to. 2.1 months for chemotherapy. Other immune related adverse events in the MPDL3280A arm included increase of enzyme levels in the blood (asparate and alanine aminotransferase; 4% each), inflammation in the lining of the colon (colitis; 1%), inflammation of the liver (hepatitis; 1%) and lung tissue (pneumonitis; 2%).
About MPDL3280A
MPDL3280A (also known as anti-PDL1 and RG7446) is an investigational monoclonal antibody designed to interfere with a protein called PD-L1. MPDL3280A is designed to target PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on the surface of T cells. By inhibiting PD-L1, MPDL3280A may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells.